RecruitingPhase 2NCT06841731

A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia

A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of HRS-8427 in the Treatment of Adults With Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP)

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Enrollment

100 participants

Start Date

Apr 3, 2025

Study Type

INTERVENTIONAL

Conditions

Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)

Summary

The purpose of this study is to evaluate the efficacy and safety of HRS -8427 in patients with HABP/VABP.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS-8427 and a drug called Meropenem for people with hospital-acquired bacterial pneumonia (habp) and ventilator-associated bacterial pneumonia (vabp). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHRS-8427

HRS-8427 for injection.

DRUGMeropenem

Meropenem for injection.

Locations(1)

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06841731

Related Trials

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex

NCT073265401 location

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

NCT070891861 location